Login
Companies $CERS
$1.86 +$0.00 (0.0%) After hours
CERUS CORP logo

CERUS CORP

cerus.com

What Do They Do?

Sells the INTERCEPT Blood System, designed to reduce pathogens in donated blood components, to blood banks, hospitals and distributors.

How Do They Make Money?

Product sales bring money from blood banks, hospitals, universities, government agencies and distributors buying kits, illuminators, fibrinogen complex and other products; invoices generally require payment 30 to 60 days after invoicing, while maintenance pays over its service term. U.S. government contracts reimburse approved project costs as the work is done or pay at milestones.

revenue
SegmentShareRevenue
Product
Mix

88%
FY2022: 86%
Government Contract
Recurring

12%
FY2022: 14%

Who Are Their Customers?

Blood banks and other health-care or government customers buy directly; distributors sell the platelet and plasma systems in some regions.

Do Revenues Turn Into Profits?

Not on paper. It lost $15.6M in FY2025, but brought in more cash than it spent: $1.1M of free cash flow.

Operating income, FY2025
−4% of revenue
▲ +39% (Loss) vs FY2024 (−$14.2M, −7%)
Net income, FY2025
−7% of revenue
▲ +25% (Loss) vs FY2024 (−$20.9M, −10%)
Free cash flow, FY2025
0% of revenue
▼ −87% vs FY2024 ($8.5M, 4%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +10%
vs $52.7M in Q3 FY2025
Net income
▼ −2795% (Loss)
vs −$19K in Q3 FY2025
Product share of revenue vs 100.0% in Q3 FY2025
  • Jul 30, 2026 Cerus raised the low end of its product revenue and IFC outlook 2026 product revenue guidance is $229 million to $231 million, and IFC sales guidance is $23 million to $25 million.
  • Jul 10, 2026 William Greenman became executive chairman after leaving the CEO role

Growing. Revenue grew 47% in 4 years, from $159.5M in FY2021 to $233.8M in FY2025, about 10% a year.

Fibrinogen Complex sales focus Cerus is shifting from selling finished INTERCEPT Fibrinogen Complex doses to hospitals toward selling kits to blood centers; the older report described direct U.S. sales of the product or kits.

Revenue over time
Product Government Contract
$250M$125M$0

Who Do They Compete With?

Competes with Grifols, Octapharma, MacoPharma International, Kedrion Biopharma, and Terumo

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support